What’s next for Moderna after S&P inclusion?
A majority of institutional investors believe Covid-19 vaccine maker Moderna's shares will decline by at least 20% by the end of 2021.
- Moderna Inc (Nasdaq: MRNA) share price rallied above US$350 this week
- The Covid-19 vaccine maker joined the S&P 500 last week to much fanfare
- Still, analysts expect the stock to dip to US$197.85 in the coming year
- Feeling bullish or bearish on Moderna shares? Open an account to get started.
Moderna stock price boosted by 50%
Shares of US-based vaccine maker Moderna, which competes with AstraZeneca, Pfizer and Johnson & Johnson, declined by 1.1% day-on-day to close at US$345.64 on Thursday (29 July 2021).
However, the counter is still up 47.1% over the past month, fuelled by news that Moderna had joined the S&P 500 last Wednesday (21 July) as the index’s top performer this year.
The S&P 500 is widely followed as a benchmark gauge of large-cap US equities. New joiners typically see their shares rally in the lead-up to the index inclusion, as investors adjust their portfolios, Bloomberg said.
As of 30 July, research teams were largely optimistic on the MRNA stock, with eight out of 17 analysts recommending ‘buy’, five suggesting ‘hold’, and four with ‘sell’ calls. Their average 12-month target price for the drugmaker was US$197.85, according to Bloomberg data.
Last week, JPMorgan gave a ‘neutral’ rating with a US$131 target, while Goldman Sachs said ‘buy’ and targeted US$299.
Jefferies strategist Will Sevush recently wrote that bulls on Moderna’s stock are ‘very few and very far between’.
What helped Moderna’s stock value to triple?
Moderna, which has grown from an early-stage biotech firm to a worldwide supplier of Covid-19 jabs, has seen its share price more than triple so far this year.
With a year-to-date gain of 209.4%, its share performance tops the S&P 500 index’s existing leader, L Brands Inc, which has risen about 104%, Bloomberg reported.
The counter reached fresh highs in the run-up to its index inclusion. Moderna’s market capitalisation surged to US$138.8 billion as of Thursday.
The company’s innovations in making messenger ribonucleic acid (mRNA) vaccines have also prompted some analysts to call Moderna the ‘Tesla of biotech’.
What’s the outlook on Moderna?
Moderna has projected sales of its Covid-19 shots could hit US$19.2 billion this year, while Wall Street consensus stands at US$18.1 billion.
For its Q2 2021 results, to be released on 05 August 2021, investors will likely shift their focus to the sustainability of its Covid-19 vaccine income and the potential impact on 2022 and 2023, said Bloomberg Intelligence analysts.
Goldman Sachs’ research team expects Moderna may be able to bring a new flu shot to the market by 2023, followed by a combination of a flu and Covid-19 vaccine in 2024 or later.
In addition, the company is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.
Nearly three-quarters of hedge funds and institutional investors - out of the 191 surveyed by Jefferies - believe that Moderna’s shares will be little changed or decline by at least 20% by the end of this year.
What’s your take on Moderna shares? Take a position on the stock today.
Go long or short with CFDs on 16,000+ shares with our award-winning platform.* Perfect your trading technique with S$200,000 of virtual funds in your free demo account. Sign up for a demo account today.
* Based on the Investment Trends 2018 Singapore CFD & FX Report based on a survey of over 4,500 traders and investors. Awarded the Best Online Trading Platform by Influential Brands in 2020. Awarded the best retail FX provider for Asia by FX Markets in 2020
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.